It’s the EMVS’s Birthday! The European Medicines Verification System’s third anniversaryExecutive summaryToday marks the third anniversary of the European Medicines Verification (“EMVS”) System Go-live. This unique system ensures patient safety by detecting falsified...
Value added Medicines | Online SummitExecutive summaryEmpowering the healthcarecommunity by improvingexisting treatments• Innovating on existing molecules in the form of repurposing,reformulation and combination of therapies has the potential to delivertimely and...
Háziorvosok is felírhatják a favipiravirt COVID-19-betegeknekAkadémikusok javaslatára Mit kell tudni a gyógyszerről és milyen esetekben alkalmazható? Erről nyilatkozott az mta.hu-nak Keserű György Miklós akadémikus, a Természettudományi Kutatóközpont Gyógyszerkémiai...
The report consists of observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets.
This series of reports has been a long-standing source of information on the status of the biosimilar market. This year, we deliver more granular insight into the categorisation of biological medicines over time, and additional data (to June 2020 MAT) to give a broader view than previous reports, and take into account the impact of the COVID-19 pandemic.
The major observations in this white paper cover: the savings potential, usage of biological medicines, originator defence strategies, biosimilar policies, and the future opportunity due to biologic loss of exclusivity.
Forrás: Medicines for Europe